Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shocking relief? electrostulation and compression soothe chemo nerve pain

NCT ID NCT07409987

Symptom relief Sponsor: Cumhuriyet University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 5 times

Summary

This study tested whether electrostimulation and compression can reduce nerve pain and improve quality of life in people with gastrointestinal cancer who developed peripheral neuropathy from oxaliplatin chemotherapy. 140 patients were split into four groups: control, electrostimulation alone, compression alone, or both. The goal was to see if these simple, non-drug approaches could ease symptoms and improve daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Aug 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Diagnosed with metastatic gastrointestinal cancer, including gastric, pancreatic, colon, or rectal cancer * Scheduled to receive six cycles of oxaliplatin-based chemotherapy with FOLFOX or FOLFIRINOX * Having received one cycle of oxaliplatin-based chemotherapy * Having Grade 2 or higher chemotherapy-induced peripheral neuropathy according to NCI-CTCAE v5.0 before the Cycle 2 intervention * Eastern Cooperative Oncology Group performance status of 0-2 * Having provided written informed consent to participate Exclusion Criteria: * Having a diagnosed psychiatric disorder that could interfere with informed consent, communication, or adherence to the study procedures * Having a cardiac pacemaker or another implanted electronic device contraindicating TENS * Having pre-existing peripheral neuropathy before the initiation of oxaliplatin-based chemotherapy or neuropathy attributable to another cause * Having diabetes mellitus * Having peripheral vascular disease or another clinically significant circulatory disorder affecting the hands or feet * Having a skin lesion or other skin condition at the sites where TENS electrodes or compression garments would be applied

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cipn - chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cipn - chemotherapy-induced peripheral neuropathy Gastrointestinal cancers Oxaliplatin Oxaliplatin induced peripheral neuropathy in cancer patients

Contacts and locations

Locations

  • Sivas Cumhuriyet University Health Services Application and Research Hospital

    Sivas, Sivas, 58010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.